A low-molecular-weight ferroxidase is increased in the CSF of sCJD cases: CSF ferroxidase and transferrin as diagnostic biomarkers for sCJD

Antioxidants and Redox Signaling

Volumn 19, Issue 14, 2013, Pages 1662-1675

  Haldar, Swati ^a   Beveridge, 'Alim J ^b   Wong, Joseph ^a   Singh, Ajay ^a   Galimberti, Daniela ^c   Borroni, Barbara ^d   Zhu, Xiongwei ^a   Blevins, Janis ^a   Greenlee, Justin ^e   Perry, George ^f   Mukhopadhyay, Chinmay K ^g   Schmotzer, Christine ^a   Singh, Neena ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF BRESCIA   (Italy)

^e NATIONAL ANIMAL DISEASE CENTER   (United States)

^f University of San Antonio   (United States)

^g JAWAHARLAL NEHRU UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PRECURSOR PROTEIN; CERULOPLASMIN; IRON; PROTEINASE K; TRANSFERRIN;

ALZHEIMER DISEASE; AREA UNDER THE CURVE; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; CREUTZFELDT JAKOB DISEASE; DEMENTIA; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; HEAT; HUMAN; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SPORADIC CREUTZFELDT JAKOB DISEASE;

BIOLOGICAL MARKERS; CERULOPLASMIN; CREUTZFELDT-JAKOB SYNDROME; HUMANS; TRANSFERRIN;

EID: 84887103102     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2012.5032     Document Type: Article

References (74)

1. Aguzzi A and Falsig J. Prion propagation, toxicity and degradation. Nat Neurosci 15: 936-939, 2012
2. Atarashi R, Satoh K, Sano K, Fuse T, Yamaguchi N, Ishibashi D, Matsubara T, Nakagaki T, Yamanaka H, Shirabe S, Yamada M, Mizusawa H, Kitamoto T, Klug G, McGlade A, Collins SJ, and Nishida N. Ultrasensitive human prion detection in cerebrospinal fluid by real-Time quaking-induced conversion. Nat Med 17: 175-178, 2011
3. Barone E, Di Domenico F, Sultana R, Coccia R, Mancuso C, Perluigi M, and Butterfield DA. Heme oxygenase-1 posttranslational modifications in the brain of subjects with Alzheimer disease and mild cognitive impairment. Free Radic Biol Med 52: 2292-2301, 2012
4. Boll MC, Alcaraz-Zubeldia M, Montes S, and Rios C. Free copper, ferroxidase and SOD1 activities, lipid peroxidation and NO(x) content in the CSF. A different marker profile in four neurodegenerative diseases. Neurochem Res 33: 1717-1723, 2008
5. Boll MC, Sotelo J, Otero E, Alcaraz-Zubeldia M, and Rios C. Reduced ferroxidase activity in the cerebrospinal fluid from patients with Parkinson's disease. Neurosci Lett 265: 155-158, 1999
6. Bonda DJ, Lee HG, Blair JA, Zhu X, Perry G, and Smith MA. Role of metal dyshomeostasis in Alzheimer's disease. Metallomics 3: 267-270, 2011
7. Cahill CM, Lahiri DK, Huang X, and Rogers JT. Amyloid precursor protein and alpha synuclein translation, implications for iron and inflammation in neurodegenerative disease. Biochim Biophys Acta 1790: 615-628, 2009
8. Calabrese V, Sultana R, Scapagnini G, Guagliano E, Sapienza M, Bella R, Kanski J, Pennisi G, Mancuso C, Stella AM, and Butterfield DA. Nitrosative stress, cellular stress response, and thiol homeostasis in patients with Alzheimer's disease. Antioxid Redox Signal 8: 1975-1986, 2006
9. Capo CR, Arciello M, Squitti R, Cassetta E, Rossini PM, Calabrese L, and Rossi L. Features of ceruloplasmin in the cerebrospinal fluid of Alzheimer's disease patients. Biometals 21: 367-372, 2008
10. Chitravas N, Jung RS, Kofskey DM, Blevins JE, Gambetti P, Leigh RJ, and Cohen ML. Treatable neurological disorders misdiagnosed as Creutzfeldt-Jakob disease. Ann Neurol 70: 437-444, 2011
11. Cho HH, Cahill CM, Vanderburg CR, Scherzer CR, Wang B, Huang X, and Rogers JT. Selective translational control of the Alzheimer amyloid precursor protein transcript by iron regulatory protein-1. J Biol Chem 285: 31217-31232, 2010
12. Chohan G, Pennington C, Mackenzie JM, Andrews M, Everington D, Will RG, Knight RS, and Green AJ. The role of cerebrospinal fluid 14-3-3 and other proteins in the diagnosis of sporadic Creutzfeldt-Jakob disease in the UK: A 10-year review. J Neurol Neurosurg Psychiatry 81: 1243-1248, 2010
13. Clardy SL, Earley CJ, Allen RP, Beard JL, and Connor JR. Ferritin subunits in CSF are decreased in restless legs syndrome. J Lab Clin Med 147: 67-73, 2006
14. Cosseddu GM, Nonno R, Vaccari G, Bucalossi C, Fernandez-Borges N, Di Bari MA, Castilla J, and Agrimi U. Ultraefficient PrP(Sc) amplification highlights potentialities and pitfalls of PMCA technology. PLoS Pathog 7: E1002370, 2011
15. Coulthart MB, Jansen GH, Olsen E, Godal DL, Connolly T, Choi BC, Wang Z, and Cashman NR. Diagnostic accuracy of cerebrospinal fluid protein markers for sporadic Creutzfeldt-Jakob disease in Canada: A 6-year prospective study. BMC Neurol 11: 133, 2011
16. Crichton RR, Dexter DT, and Ward RJ. Brain iron metabolism and its perturbation in neurological diseases. J Neural Transm 118: 301-314, 2011
17. Davies P, Moualla D, and Brown DR. Alpha-synuclein is a cellular ferrireductase. PLoS One 6: E15814, 2011
18. DeLong ER, DeLong DM, and Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach. Biometrics 44: 837-845, 1998
19. Di Domenico F, Barone E, Mancuso C, Perluigi M, Cocciolo A, Mecocci P, Butterfield DA, and Coccia R. HO-1/BVR- system analysis in plasma from probable Alzheimer's disease and mild cognitive impairment subjects: A potential biochemical marker for the prediction of the disease. J Alzheimers Dis 32: 277-289, 2012
20. Djoko KY, Chong LX, Wedd AG, and Xiao Z. Reaction mechanisms of the multicopper oxidase CueO from Escherichia coli support its functional role as a cuprous oxidase. J Am Chem Soc 132: 2005-2015, 2010
21. Doran M and Larner AJ. EEG findings in dementia with Lewy bodies causing diagnostic confusion with sporadic Creutzfeldt-Jakob disease. Eur J Neurol 11: 838-841, 2004
22. Duce JA, Tsatsanis A, Cater MA, James SA, Robb E, Wikhe K, Leong SL, Perez K, Johanssen T, Greenough MA, Cho HH, Galatis D, Moir RD, Masters CL, McLean C, Tanzi RE, Cappai R, Barnham KJ, Ciccotosto GD, Rogers JT, and Bush AI. Iron-export ferroxidase activity of b-Amyloid precursor protein is inhibited by zinc in Alzheimer's Disease. Cell 142: 857-867, 2010
23. Friedlich AL, Tanzi RE, and Rogers JT. (2007) The 5¢-untranslated region of Parkinson's disease alpha-synuclein messenger RNA contains a predicted iron responsive element. Mol Psychiatry 12: 222-223, 2007
24. Gaig C, Valldeoriola F, Gelpi E, Ezquerra M, Llufriu S, Buongiorno M, Jesú s Rey M, Jose Martí M, Graus F, and Tolosa E. Rapidly progressive diffuse Lewy body disease. Mov Disord 26: 1316-1323, 2011
25. Geschwind MD, Haman A, and Miller BL. Rapidly progressive dementia. Neurol Clin 25: 783-807, 2007
26. Geschwind MD, Martindale J, Miller D, DeArmond SJ, Uyehara-Lock J, Gaskin D, Kramer JH, Barbaro NM, and Miller BL. Challenging the clinical utility of the 14-3-3 protein for the diagnosis of sporadic Creutzfeldt-Jakob disease. Arch Neurol 60: 813-816, 2003
27. Geschwind MD, Shu H, Haman A, Sejvar JJ, and Miller BL. Rapidly progressive dementia. Ann Neurol 64: 97-108, 2008
28. Gray LW, Kidane TZ, Nguyen A, Akagi S, Petrasek K, Chu YL, Cabrera A, Kantardjieff K, Mason AZ, and Linder MC. Copper proteins and ferroxidases in human plasma and that of wild-Type and ceruloplasmin knockout mice. Biochem J 419: 237-245, 2009
29. Haïk S, Brandel JP, Sazdovitch V, Delasnerie-Lauprêtre N, Peoćh K, Laplanche J-L, Privat N, Duyckaerts C, Kemeny JL, Kopp N, Laquerrière A, Mohr M, Deslys JP, Dormont D, and Hauw JJ. Dementia with Lewy bodies in a neuropathologic series of suspected Creutzfeldt-Jakob disease. Neurology 55: 1401-1404, 2000
30. Hamlin C, Puoti G, Berri S, Sting E, Harris C, Cohen M, Spear C, Bizzi A, Debanne SM, and Rowland DY. A comparison of tau and 14-3-3 protein in the diagnosis of Creutzfeldt-Jakob disease. Neurology 79: 547-552, 2012
31. Heinemann U, Krasnianski A, Meissner B, Varges D, Kallenberg K, Schulz-Schaeffer WJ, Steinhoff BJ, Grasbon-Frodl EM, Kretzschmar HA, and Zerr I. Creutzfeldt-Jakob disease in Germany: A prospective 12-year surveillance. Brain 130: 1350-1359, 2007
32. Hilditch-Maguire P, Trettel F, Passani LA, Auerbach A, Persichetti F, and MacDonald ME. (2000) Huntingtin: An iron regulated protein essential for normal nuclear and perinuclear organelles. Hum Mol Genet 9: 2789-2797, 2000
33. Holtzman DM. CSF biomarkers for Alzheimer's disease: current utility and potential future use. Neurobiology 32: S4-S9, 2011
34. Hwang D, Lee IY, Yoo H, Gehlenborg N, Cho JH, Petritis B, Baxter D, Pitstick R, Young R, Spicer D, Price ND, Hohmann JG, Dearmond SJ, Carlson GA, and Hood LE. A systems approach to prion disease. Mol Syst Biol 5: 252, 2009
35. Jayaratnam S, Khoo AK, and Basic D. Rapidly progressive Alzheimer's disease and elevated 14-3-3 proteins in cerebrospinal fluid. Age Ageing 37: 467-469, 2008
36. Jeong SY and David S. Glycosylphosphatidylinositol-Anchored ceruloplasmin is required for iron efflux from cells in the central nervous system. J Biol Chem278: 27144-27148, 2003
37. Kell DB. Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples. Arch Toxicol 84: 825-889, 2010
38. Khalil M, Teunissen C, and Langkammer C. Iron and neurodegeneration in multiple sclerosis. Mult Scler Int 2011: 606807, 2011
39. Lee GR, Nacht S, Christensen D, Hansen SP, and Cartwright GE. The contribution of citrate to the ferroxidase activity of serum. Exp Biol Med 131: 918-923, 1969
40. MacKenzie EL, Iwasaki K, and Tsuji Y. Intracellular iron transport and storage: From molecular mechanisms to health implications. Antioxid Redox Signal 10: 997-1030, 2001
41. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosén E, Aarsland D, Visser PJ, Schröder J, Marcusson J, De Leon M, Hampel H, Scheltens P, Pirttilä T, Wallin A, Jönhagen ME, Minthon L, Winblad B, and Blennow K. CSF Biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302: 385-393, 2009
42. Menard S. Applied Logistic Regression Analysis. Sage University Paper Series on Quantitative Applications in the Social Sciences, 07-106. Thousand Oaks, CA: Sage, 1995
43. Meyne F, Gloeckner SF, Ciesielczyk B, Heinemann U, Krasnianski A,Meissner B, and Zerr I. Total prion protein levels in the cerebrospinal fluid are reduced in patients with various neurological disorders. J Alzheimers Dis 17: 863-873, 2009
44. Moos T and Morgan EH. The metabolism of neuronal iron and its pathogenic role in neurological disease: Review. Ann N Y Acad Sci 1012: 14-26, 2004
45. Moos T, Rosengren Nielsen T, Skjørringe T, and Morgan EH. Iron trafficking inside the brain. J Neurochem 103: 1730-1740, 2007
46. Muayqil T, Gronseth G, and Camicioli R. Evidence-based guideline: Diagnostic accuracy of CSF 14-3-3 protein in sporadic Creutzfeldt-Jakob disease: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 79: 1499-1506, 2012
47. Newcombe RG. Two-sided confidence intervals for the single proportion: Comparison of seven methods. Stat Med 17: 857-872, 1998
48. Olivieri S, Conti A, Iannaccone S, Cannistraci CV, Campanella A, Barbariga M, Codazzi F, Pelizzoni I, Magnani G, Pesca M, Franciotta D, Cappa SF, and Alessio M. Ceruloplasmin oxidation, a feature of Parkinson's disease CSF, inhibits ferroxidase activity and promotes cellular iron retention. J Neurosci 31: 18568-18577, 2011
49. Orrú CD, Wilham JM, Hughson AG, Raymond LD, McNally KL, Bossers A, Ligios C, and Caughey B. Human variant Creutzfeldt-Jakob disease and sheep scrapie PrP(res) detection using seeded conversion of recombinant prion protein. Protein Eng Des Sel 22: 515-521, 2009
50. Pennington C, Chohan G, Mackenzie J, Andrews M, Will R, Knight R, and Green A. The role of cerebrospinal fluid proteins as early diagnostic markers for sporadic Creutzfeldt-Jakob disease. Neurosci Lett 455: 56-59, 2009
51. Perry DC and Geschwind MD. Thorough work-up and new diagnostic criteria needed for CJD. Nat Rev Neurol 7: 479-480, 2011
52. Pham AN and Waite TD. Modeling the kinetics of Fe(II) oxidation in the presence of citrate and salicylate in aqueous solutions at pH 6.0-8.0 and 25 30)degrees C. J Phys Chem A 112: 5395-5405, 2008
53. Puoti G, Bizzi A, Forloni G, Safar JG, Tagliavini F, and Gambetti P. Sporadic human prion diseases: Molecular insights and diagnosis. Lancet Neurol 11: 618-628, 2012
54. Schmidt C, Wolff M, Weitz M, Bartlau T, Korth C, and Zerr I. Rapidly progressive Alzheimer disease. Arch Neurol 68: 1124-1130, 2011
55. Sfagos C, Makis AC, Chaidos A, Hatzimichael EC, Dalamaga A, Kosma K, and Bourantas KL. Serum ferritin, transferrin and soluble transferrin receptor levels in multiple sclerosis patients. Mult Scler 11: 272-275, 2005
56. Shaw LM, Korecka M, Clark CM, Lee VM, and Trojanowski JQ. Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nat Rev Drug Discov 6: 295-303, 2007
57. Siman R, Giovannone N, Toraskar N, Frangos S, Stein SC, Levine JM, and Kumar MA. Evidence that a panel of neurodegeneration biomarkers predicts vasospasm, infarction, and outcome in aneurysmal subarachnoid hemorrhage. PLoS One 6: E28938, 2011
58. Simel DL, Samsa GP, and Matchar DB. Likelihood ratios with confidence: Sample size estimation for diagnostic test studies. J Clin Epidemiol 44: 763-770, 1991
59. Singh A, Beveridge AJ, and Singh N. Decreased CSF Transferrin in sCJD: A Potential Pre-Mortem Diagnostic Test for Prion Disorders. PLoS One 6: E16804, 2011
60. Singh A, Isaac AO, Luo X, Mohan, ML, Bartz J, and Singh N. Abnormal brain iron homeostasis in human and animal prion disorders. PLoS Pathog 5: E1000336, 2009
61. Singh A, Kong Q, Luo X, Petersen RB, Meyerson H, and Singh N. Prion protein (PrP) knock-out mice show altered iron metabolism: A functional role for PrP in iron uptake and transport. PLoS One 4: E6115, 2009
62. Singh A, Mohan ML, Isaac AO, Luo X, Petrak J, Vyoral D, and Singh N. Prion protein modulates cellular iron uptake: A novel function with implications for disease pathogenesis. PLoS One 4: E4468, 2009
63. Singh A, Qing L, Kong Q, and Singh N (2012) Change in the characteristics of ferritin induces iron imbalance in prion disease affected brains. Neurobiol Dis 45: 930-938, 2012
64. Singh N, Das D, Singh A, and Mohan ML. Prion protein and metal interaction: Physiological and pathological implications. Curr Issues Mol Biol 12: 99-107, 2010
65. Singh N, Singh A, Das D, and Mohan ML. Redox control of prion and disease pathogenesis. Antioxid Redox Signal 12: 1271-1294, 2010
66. Taipa R, Pinho J, and Melo-Pires M. Clinico-pathological correlations of the most common neurodegenerative dementias. Front Neurol 3: 68, 2012
67. Tartaglia MC, Johnson DY, Thai JN, Cattaruzza T, Wong K, Garcia P, Dearmond SJ, Miller BL, and Geschwind MD. Clinical overlap between Jakob-Creutzfeldt disease and Lewy body disease. Can J Neurol Sci 39: 304-310, 2012
68. Thompson KJ, Shoham S, and Connor JR. Iron and neurodegenerative disorders. Brain Res Bull 55: 155-164, 2001
69. Torres M, Cartier L, Matamala JM, Hernández N, Woehlbier U, and Hetz C. Altered Prion protein expression pattern in CSF as a biomarker for Creutzfeldt-Jakob disease. PLoS One 7: E36159, 2012
70. Tschampa HJ, Neumann M, Zerr I, Henkel K, Schrö ter A, Schulz-Schaeffer WJ, Steinhoff BJ, Kretzschmar HA, and Poser S. Patients with Alzheimer's disease and dementia with Lewy bodies mistaken for Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 71: 33-39, 2001
71. Watts JC, Balachandran A, and Westaway D. The expanding universe of prion diseases. PLoS Pathog 2: E26, 2006
72. Wolozin B and Golts N. Iron and Parkinson's disease. Neuroscientist 8: 22-32, 2002
73. World Health Organization. Consensus on criteria for sporadic CJD. Wkly Epidemiol Rec 73: 361-365, 1998
74. Zerr I, Kallenberg K, Summers DM, Romero C, Taratuto A, Heinemann U, Breithaupt M, Varges D, Meissner B, Ladogana A, Schuur M, Haik S, Collins SJ, Jansen GH, Stokin GB, Pimentel J, Hewer E, Collie D, Smith P, Roberts H, Brandel JP, van Duijn C, Pocchiari M, Begue C, Cras P, Will RG, and Sanchez-Juan P. Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Brain 132: 2659-2668, 2009